Cells from healthy individuals with major depressive disorder were found to have higher than expected rates of methylation at specific sites on their DNA, when compared to cells from healthy individuals without MDD, according to a study by a multidisciplinary team of Walter Reed Army Institute of Research and University of California San Francisco scientists, celexa from withdrawal in collaboration with others.
Methylation is a process by which DNA is chemically modified at specific sites, resulting in changes in the expression of certain genes. Methylation of particular sets of genes, called "DNA methylation clocks," typically change in predictable ways as people age, but the rate of these changes varies between people. Methylation patterns in individuals with MDD suggested that their DNA methylation cellular age was, on average, accelerated relative to matched healthy controls.
In the study, published in Translational Psychiatry, blood samples from 49 individuals with MDD were compared to 60 healthy control subjects of the same chronological age using the 'GrimAge' clock–a mathematical algorithm designed to predict an individual's remaining lifespan based on cellular methylation patterns. Individuals with MDD showed a significantly higher GrimAge score, suggesting increased mortality risk compared to healthy individuals of the same chronological age–an average of approximately two years on the GrimAge clock.
The individuals with MDD were unmedicated prior to the study and showed no outward signs of age-related pathology, as they and the healthy controls were screened for physical health before entry into the study. The methylation patterns associated with mortality risk persisted even after accounting for lifestyle factors like smoking and BMI. These findings provide new insight into the increased mortality and morbidity associated with the condition, suggesting that there is an underlying biological mechanism accelerating cellular aging in some MDD sufferers.
"This is shifting the way we understand depression, from a purely mental or psychiatric disease, limited to processes in the brain, to a whole-body disease," said Katerina Protsenko, a medical student at UCSF and lead author of the study. "This should fundamentally alter the way we approach depression and how we think about it–as a part of overall health."
MDD is one of the most prevalent health concerns globally. According to the World health Organization, some 300 million people (4.4% of the population) suffer from some form of depression. MDD is associated with higher incidence and mortality related to increased rates of cardiovascular disease, diabetes, and Alzheimer's disease among sufferers.
"One of the things that's remarkable about depression is that sufferers have unexpectedly higher rates of age-related physical illnesses and early mortality, even after accounting for things like suicide and lifestyle habits," said Dr. Owen Wolkowitz, professor of psychiatry and a member of UCSF's Weill Institute for Neurosciences, co-senior author of the study. "That's always been a mystery, and that's what led us to look for signs of aging at the cellular level."
The researchers say that they don't yet know if depression causes altered methylation in certain individuals, or if depression and methylation are both related to another underlying factor. It is possible that some individuals may have a genetic predisposition to produce specific methylation patterns in response to stressors, but this has not been well-studied. Alterations in methylation patterns have previously been observed in individuals with post-traumatic stress disorder.
"These findings will allow us to better understand the relationships between behavioral health disorders–for example, 60% of PTSD cases are co-morbid with MDD. Elucidating these mechanistic and biochemical underpinnings will improve efforts to develop targeted diagnostic and treatment strategies, ultimately improving patient care," said Dr. Marti Jett, WRAIR chief scientist. Previous research from the group used GrimAge to study men with combat PTSD.
Moving forward, the researchers hope to determine whether pharmacological treatments or therapy may mitigate some methylation changes related to MDD in hopes of normalizing the cellular aging process in affected individuals before it advances. Also, although the "GrimAge" methylation clock has been associated with mortality in other populations, no studies have yet prospectively determined whether this methylation pattern also predicts mortality in MDD.
"As we continue our studies, we hope to find out whether addressing the MDD with anti-depressants or other treatments alters the methylation patterns, which would give us some indication that these patterns are dynamic and can be changed," said Dr. Synthia Mellon, professor in the Department of Obstetrics, Gynecology and the Reproductive Sciences at UCSF and co-senior author of the study.
Walter Reed Army Institute of Research
Protsenko, E., et al. (2021) “GrimAge,” an epigenetic predictor of mortality, is accelerated in major depressive disorder. Translational Psychiatry. doi.org/10.1038/s41398-021-01302-0.
Posted in: Medical Science News | Medical Research News | Medical Condition News
Tags: Aging, Alzheimer's Disease, Blood, Brain, Cardiovascular Disease, Depression, Depressive Disorder, Diabetes, Diagnostic, DNA, DNA Methylation, Drugs, Genes, Genetic, Gynecology, Infectious Diseases, Major Depressive Disorder, Medical Research, Medicine, Mortality, Obstetrics, Pathology, Post-Traumatic Stress Disorder, Psychiatry, Research, Smoking, Stress, Vaccine
Source: Read Full Article